Evidence map›Paper›PMID 29700084›Full record

ReviewCirculation research2018

Reactive Oxygen Species in Metabolic and Inflammatory Signaling.

Steven J Forrester, Daniel S Kikuchi, Marina S Hernandes, Qian Xu, Kathy K Griendling

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05908513 (Randomized Study on N-acetylcysteine Treatment and Outcomes in Patients With Advanced Atherosclerotic Heart Diseases and Diabetes Mellitus), which is not on this map. Cited by 1,074 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,074citing papers in PubMed, 1 pooled it
95.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05908513 phase1withdrawnnot on this mapstarted 2021, after this paper: background citation

Randomized Study on N-acetylcysteine Treatment and Outcomes in Patients With Advanced Atherosclerotic Heart Diseases and Diabetes Mellitus (RENEWAL)

TypeinterventionalSponsorUniversity of Missouri-ColumbiaRan2021 to 2021Enrolled0ConditionsAtherosclerosis of Artery, Peripheral Artery Disease, Diabetes Mellitus, InflammationArmsN-acetylcysteine, Placebo
3 · Its place in the literature

Who cites it

1,074 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,950 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. BiogenicRSC advances · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  18. Review
  19. Article
  20. Review

1,014 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Steven J ForresterFrom the Division of Cardiology, Department of Medicine, Emory University, Atlanta GA.
Daniel S KikuchiFrom the Division of Cardiology, Department of Medicine, Emory University, Atlanta GA.
Marina S HernandesFrom the Division of Cardiology, Department of Medicine, Emory University, Atlanta GA.
Qian XuFrom the Division of Cardiology, Department of Medicine, Emory University, Atlanta GA.
Kathy K GriendlingFrom the Division of Cardiology, Department of Medicine, Emory University, Atlanta GA. kgriend@emory.edu.
Emory University · USCarter Center · US

Funding

T cell triggering events and hypertensionP01HL095070 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2009 to 2019
$20.5M
Research Trainng in Academic CardiologyT32HL007745 · NHLBI · EMORY UNIVERSITY · PI TAYLOR, WILLIAM ROBERT · 1994 to 2023
$10.6M
American Heart Association-American Stroke Association 17SDG33410777NHLBI NIH HHS P01 HL095070NHLBI NIH HHS T32 HL007745
6 · The paper itself

Abstract

Reactive oxygen species (ROS) are well known for their role in mediating both physiological and pathophysiological signal transduction. Enzymes and subcellular compartments that typically produce ROS are associated with metabolic regulation, and diseases associated with metabolic dysfunction may be influenced by changes in redox balance. In this review, we summarize the current literature surrounding ROS and their role in metabolic and inflammatory regulation, focusing on ROS signal transduction and its relationship to disease progression. In particular, we examine ROS production in compartments such as the cytoplasm, mitochondria, peroxisome, and endoplasmic reticulum and discuss how ROS influence metabolic processes such as proteasome function, autophagy, and general inflammatory signaling. We also summarize and highlight the role of ROS in the regulation metabolic/inflammatory diseases including atherosclerosis, diabetes mellitus, and stroke. In order to develop therapies that target oxidative signaling, it is vital to understand the balance ROS signaling plays in both physiology and pathophysiology, and how manipulation of this balance and the identity of the ROS may influence cellular and tissue homeostasis. An increased understanding of specific sources of ROS production and an appreciation for how ROS influence cellular metabolism may help guide us in the effort to treat cardiovascular diseases.

Indexed as

AnimalsCardiovascular DiseasesHumansMetabolic DiseasesReactive Oxygen SpeciesSignal TransductionReactive Oxygen Speciescardiovascular diseasesinflammationmetabolismoxidative stresssignal transduction

Identifiers

PMID29700084
PMCPMC5926825
OpenAlexW2791564057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.